Conference Coverage

Clinical Trial of Transdominant Rev Underway

Published in Cancer Weekly, February 20th, 1995

Three patients with HIV infection have received five transfers of autologous T cells carrying a gene construct - Rev M10 - that suppresses HIV replication without affecting T-cell function.

All three patients have received transfers of at least 1 billion cells, and two have received transfers of 10 billion cells. In all, 12 patients are enrolled in the Phase I study, reported University of Michigan researcher Gary Nabel at the 2nd National Conference on Human Retroviruses and Related Infections, held January 29-February 2, 1995, in Washington, D.C.

The Rev M10 construct is one of three anti-HIV gene therapy strategies currently in Phase I clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry